September 10, 2014

ADMA Biologics' Plasma Collection Subsidiary ADMA BioCenters Norcross, GA Facility Expands Global Regulatory Approval Presence

Includes: United States, Europe and South Korea

RAMSEY, N.J.-- ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its wholly owned subsidiary, ADMA BioCenters in Norcross, Georgia, received approval from the Korean Ministry of Food and Drug Safety (MFDS) for the sale of source plasma into South Korea.

"We are very pleased to receive Korean MFDS approval for our plasma collection facility," stated Adam Grossman, President and Chief Executive Officer of ADMA. "This approval further enhances our existing global presence as a source plasma provider, which includes the U.S., Europe and now South Korea. This regulatory milestone is a result of ADMA's commitment to quality and adherence to the regulatory requirements of the global plasma community."

ADMA BioCenters, Norcross, Georgia facility is a Food and Drug Administration (FDA) licensed, German Health Authority (GHA) and Korean MFDS approved facility and is also a member of the International Quality Plasma Program (IQPP) as certified by the Plasma Protein Therapeutics Association (PPTA).

About ADMA BioCenters

ADMA BioCenters is a wholly-owned subsidiary of ADMA Biologics, which operates as a source plasma collection business. ADMA BioCenters holds FDA, GHA and MFDS licenses to operate as a source plasma collection organization for both U.S. based and foreign fractionators' therapeutic plasma products manufacturing.

A typical plasma collection center can collect between 30,000 to 50,000 liters of source plasma annually. Plasma collected from ADMA BioCenters that is not used in the production of RI-002 is sold to customers under an existing supply agreement or in the open "spot" market generating revenues for the company. Additional information may be obtained from the ADMA BioCenters website: www.atlantaplasma.com.

About ADMA Biologics, Inc.

ADMA is a late stage biopharmaceutical company that develops, manufactures, and intends

to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-compromised for medical reasons. ADMA also operates ADMA BioCenters, an FDA-licensed, GHA-certified and Korean MFDS approved source plasma collection organization which provides ADMA with a portion of its blood plasma for the manufacture of RI-002. For more information, please visit the Company's website at www.admabiologics.com.

About ADMA's lead product candidate RI-002

ADMA's lead product candidate, RI-002 is a specialty plasma-derived, polyclonal, Intravenous Immune Globulin, or IGIV, derived from human plasma containing naturally occurring polyclonal antibodies (e.g., streptococcus pneumoniae, H. influenza type B, Cytomegalovirus (CMV), measles, tetanus, etc.) as well as high levels of antibodies targeted to respiratory syncytial virus (RSV). ADMA is pursuing an indication for the use of this specialty IGIV product for treatment of patients diagnosed with primary immune deficiency diseases, or PIDD. Polyclonal antibodies are the primary component of IGIV products. Polyclonal antibodies are proteins produced by B-cells that are used by the body's immune system to neutralize microbes, such as bacteria and viruses. The polyclonal antibodies that are present in RI-002 are expected to prevent infections in immune-compromised patients. The product is currently being evaluated in a Phase III trial in the United States with preliminary data expected to be announced during the fourth quarter of 2014.

Cautionary Statement Regarding Forward-Looking Information

This press release contains "forward looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "target," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning the amounts of source plasma that can be collected annually, the timing, progress and results of the clinical development, the availability of preliminary data, the reporting of data, regulatory processes, potential clinical trial initiations, potential investigational new product applications, biologics license applications, expansion plans, the achievement of clinical and regulatory milestones, build out, opening and regulatory approval of plasma facilities, commercialization efforts of the Company's product candidate(s), trends relating to demand for source plasma and our ability to sell such plasma. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks listed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the U.S. Securities and Exchange Commission on March 28, 2014 and our other filings with the U.S. Securities and Exchange Commission including, among other things, risks as to whether any preliminary data will, if and when available, be encouraging, positive or will otherwise lead to an effective or approved product,

whether we will be able to demonstrate efficacy or gain necessary approvals to market and commercialize any product, whether we will meet any of our clinical or regulatory milestones, open any new facilities, changes in supply and demand for source plasma and whether we will meet any timing targets expressed by the Company. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent to the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward looking statements or to announce revisions to any of the forward-looking statements.

ADMA Biologics, Inc.
Brian Lenz, 201-478-5552
Vice President and Chief Financial Officer
www.admabiologics.com

Source: ADMA Biologics, Inc.